Cord Blood News Volume 6.29 | Jul 31 2014

Immune Regulatory Properties of CD117^pos Amniotic Fluid Stem Cells Vary According to Gestational Age
Researchers analyzed the in vitro immunological properties of amniotic fluid stem cells from different gestational age in coculture with T, B and NK cells. [Stem Cells Dev] Abstract

In Vitro Immunomodulatory Effects of Microencapsulated Umbilical Cord Wharton Jelly-Derived Mesenchymal Stem Cells in Primary Sjögren’s Syndrome
Scientists aimed to assess the in vitro effects of IFN-γ-pretreated microencapsulated-human umbilical cord Wharton jelly-derived mesenchymal stem cells on T cells of primary Sjögren’s syndrome. [Rheumatology] Abstract

The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface
Scientists analyzed CD52 expression and the effects of CAMPATH-1H on fresh or frozen, resting or activated, peripheral blood mononuclear cells and cord blood mononuclear cells. [PLoS One] Full Article

Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources
Researchers compared total hospital length of stay in the first 100 days after hematopoietic cell transplantation (HCT) in 1577 patients with acute leukemia in remission receiving umbilical cord blood, matched unrelated donor or mismatched unrelated donors HCT. [Biol Blood Marrow Transplant] Abstract

Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Non-Follicular Indolent Lymphoma
Scientists describe a multicenter, retrospective cohort study of patients with biopsy-proven indolent B-cell non-follicular non-Hodgkin lymphoma, and simultaneous or subsequent biopsy-proven aggressive histology transformation who were treated with allogeneic and autologous stem cell transplantation. [Biol Blood Marrow Transplant] Abstract

HHV-6 Reactivation before Engraftment Is Strongly Predictive of Graft Failure after Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults
Investigators aimed to determine new factors associated with engraftment and single-unit predominance after double umbilical cord blood allogeneic stem-cell transplant. [Exp Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Innate Pharma SA Announces Completion of Target Enrollment in the Phase II EffiKIR Trial
Innate Pharma SA announced completion of target enrollment in the EffiKIR trial with 150 patients randomized. EffiKIR is a double-blind placebo-controlled randomized Phase II trial of lirilumab as maintenance treatment in elderly patients with acute myeloid leukemia in first complete remission. [Innate Pharma SA] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Hematopoietic Stem Cell Scientist – Human Genetic Disorders (Editas Medicine)

Biologist or Immunologist – Hematology and Stem Cell Transplantation (University Hospital Aachen)

Postdoctoral Researcher – Hematopoietic Stem Cell Maintenance (Baylor College of Medicine)

Postdoctoral Fellow – Fetal Imprinting and Establishment of the Methylome in Cord Tissue and Placenta (University of Freiburg)

Hematology Investigator (Case Western Reserve University)

Cord Tissue Processing Technician (Cord Blood Registry)

Postdoctoral Position – Hematopoietic Stem Cell Research (UT Southwestern Medical Center at Dallas)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.